Aliases & Classifications for Lentigines

MalaCards integrated aliases for Lentigines:

Name: Lentigines 58 56
Lentigo 74

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
lentigines:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 58 150900
MedGen 43 C0023321
UMLS 74 C0023321

Summaries for Lentigines

MalaCards based summary : Lentigines, also known as lentigo, is related to noonan syndrome with multiple lentigines and melanocytic nevus syndrome, congenital. An important gene associated with Lentigines is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are Sertoli-Sertoli Cell Junction Dynamics and CCR5 Pathway in Macrophages. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, pituitary and pancreas, and related phenotypes are nystagmus and abnormality of the skin

Wikipedia : 77 A lentigo (/lɛnˈtaɪɡoʊ/) (plural lentigines, /lɛnˈtɪdʒɪniːz/) is a small pigmented spot on the skin with... more...

Description from OMIM: 150900

Related Diseases for Lentigines

Diseases related to Lentigines via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 noonan syndrome with multiple lentigines 33.5 BRAF PTPN11 RAF1
2 melanocytic nevus syndrome, congenital 32.3 MC1R PRKAR1A
3 leopard syndrome 32.1 BRAF PTPN11 RAF1
4 noonan syndrome 1 31.6 BRAF PTPN11 RAF1
5 hypertrophic cardiomyopathy 29.5 BRAF PTPN11 RAF1
6 hypertelorism 29.2 BRAF PTPN11 RAF1
7 acral lentiginous melanoma 12.7
8 leopard syndrome 1 12.0
9 gastrocutaneous syndrome 11.8
10 lentiginosis, inherited patterned 11.5
11 carney complex variant 11.4
12 phacomatosis pigmentokeratotica 11.4
13 dyschromatosis universalis hereditaria 1 11.4
14 phakomatosis pigmentokeratotica 11.4
15 uv-sensitive syndrome 11.2
16 nevoid hypermelanosis, linear and whorled 11.1
17 spastic paraplegia 23, autosomal recessive 11.0
18 legius syndrome 11.0
19 leopard syndrome 2 11.0
20 leopard syndrome 3 11.0
21 melanoma 10.9
22 pseudo-turner syndrome 10.4
23 neutrophil migration 10.2
24 melanoma in congenital melanocytic nevus 10.2
25 peutz-jeghers syndrome 10.2
26 psoriasis 10.2
27 mycosis fungoides 10.0
28 vitiligo-associated multiple autoimmune disease susceptibility 1 10.0
29 nodular malignant melanoma 10.0
30 sarcoma 10.0
31 neuropathy 10.0
32 tièche-jadassohn nevus 10.0
33 mastocytosis, cutaneous 9.9
34 neurofibromatosis, type i 9.9
35 neurofibromatosis, type iv, of riccardi 9.9
36 becker nevus syndrome 9.9
37 gastrointestinal stromal tumor 9.9
38 muscle hypertrophy 9.9
39 mucosal melanoma 9.9
40 dyschromatosis universalis hereditaria 9.9
41 urticaria 9.9
42 dermatitis 9.9
43 lipomatosis 9.9
44 skin carcinoma 9.9
45 pituitary adenoma 9.9
46 pustulosis of palm and sole 9.9
47 adenoma 9.9
48 muscular atrophy 9.9
49 rosacea 9.9
50 dermatophytosis 9.9

Graphical network of the top 20 diseases related to Lentigines:



Diseases related to Lentigines

Symptoms & Phenotypes for Lentigines

Human phenotypes related to Lentigines:

33
# Description HPO Frequency HPO Source Accession
1 nystagmus 33 HP:0000639
2 abnormality of the skin 33 HP:0000951

Symptoms via clinical synopsis from OMIM:

58
Eyes:
nystagmus

Skin:
lentigines

Clinical features from OMIM:

150900

GenomeRNAi Phenotypes related to Lentigines according to GeneCards Suite gene sharing:

27 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.7 BRAF
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.7 RAF1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.7 PTPN11
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.7 PTPN11
5 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.7 PTPN11
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.7 BRAF PTPN11 RAF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.7 RAF1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.7 RAF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.7 BRAF
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.7 BRAF
11 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.7 PTPN11
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.7 PTPN11
13 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.7 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.7 BRAF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.7 BRAF
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.7 BRAF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.7 PTPN11
18 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.7 BRAF PTPN11
19 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.7 RAF1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.7 PTPN11
21 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.7 PTPN11

MGI Mouse Phenotypes related to Lentigines:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.96 BRAF MC1R PRKAR1A PTPN11 RAF1
2 cellular MP:0005384 9.95 BRAF MC1R PRKAR1A PTPN11 RAF1
3 craniofacial MP:0005382 9.93 BRAF MC1R PRKAR1A PTPN11 RAF1
4 growth/size/body region MP:0005378 9.91 BRAF MC1R PRKAR1A PTPN11 RAF1
5 hematopoietic system MP:0005397 9.88 BRAF MC1R PRKAR1A PTPN11 RAF1
6 immune system MP:0005387 9.85 BRAF MC1R PRKAR1A PTPN11 RAF1
7 embryo MP:0005380 9.83 BRAF PRKAR1A PTPN11 RAF1
8 integument MP:0010771 9.83 BRAF MC1R PRKAR1A PTPN11 RAF1
9 hearing/vestibular/ear MP:0005377 9.8 BRAF MC1R PTPN11 RAF1
10 neoplasm MP:0002006 9.72 BRAF MC1R PRKAR1A PTPN11 RAF1
11 liver/biliary system MP:0005370 9.71 BRAF PRKAR1A PTPN11 RAF1
12 muscle MP:0005369 9.67 BRAF PRKAR1A PTPN11 RAF1
13 normal MP:0002873 9.56 BRAF PRKAR1A PTPN11 RAF1
14 pigmentation MP:0001186 9.46 BRAF MC1R PRKAR1A PTPN11
15 respiratory system MP:0005388 9.26 BRAF PRKAR1A PTPN11 RAF1
16 vision/eye MP:0005391 8.92 BRAF PRKAR1A PTPN11 RAF1

Drugs & Therapeutics for Lentigines

Drugs for Lentigines (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99011-02-6 57469
3
Everolimus Approved Phase 4,Phase 2 159351-69-6 70789204 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 46835353 5284616 6436030
6 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
7 Photosensitizing Agents Phase 4,Phase 3
8 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
9 interferons Phase 4,Phase 3,Phase 2,Not Applicable
10 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Not Applicable
11 Interferon Inducers Phase 4,Phase 3,Phase 2,Not Applicable
12 Immunosuppressive Agents Phase 4,Phase 2
13 Antibiotics, Antitubercular Phase 4,Phase 2,Not Applicable
14 Anti-Bacterial Agents Phase 4,Phase 2,Not Applicable
15 Antifungal Agents Phase 4,Phase 2
16 Anti-Infective Agents Phase 4,Phase 2,Phase 1
17
Adapalene Approved Phase 3 106685-40-9 60164
18
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2 302-79-4 444795 5538
19 Keratolytic Agents Phase 3,Phase 2,Not Applicable
20 Anti-Inflammatory Agents, Non-Steroidal Phase 3
21 Analgesics Phase 3
22 Antirheumatic Agents Phase 3
23 Anti-Inflammatory Agents Phase 3,Phase 2,Not Applicable
24 Emollients Phase 3
25 Analgesics, Non-Narcotic Phase 3
26 Peripheral Nervous System Agents Phase 3,Not Applicable
27 Methyl 5-aminolevulinate Phase 3
28
Glycolic acid Approved, Investigational Phase 2 79-14-1 757
29
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 2 67-73-2 6215
30
Hydroquinone Approved, Investigational Phase 2 123-31-9 785
31
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 54670067 5785
32
Cediranib Investigational Phase 2 288383-20-0 9933475
33
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
34 Antioxidants Phase 2
35 Vitamins Phase 2,Not Applicable
36 Nutrients Phase 2,Not Applicable
37 Trace Elements Phase 2,Not Applicable
38 Protective Agents Phase 2
39 Micronutrients Phase 2,Not Applicable
40 Hormones Phase 2,Not Applicable
41 Radiation-Protective Agents Phase 2
42 Hormone Antagonists Phase 2,Not Applicable
43 glucocorticoids Phase 2,Not Applicable
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Not Applicable
45 Protein Kinase Inhibitors Phase 2
46
Ganciclovir Approved, Investigational Phase 1 82410-32-0 3454
47 Antiviral Agents Phase 1
48 Nucleic Acid Synthesis Inhibitors Phase 1
49 Ganciclovir triphosphate Phase 1
50
Neomycin Approved, Vet_approved Not Applicable 1404-04-2 8378

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
2 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
3 Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome Recruiting NCT03781050 Phase 4 Rapamycin
4 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
5 Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face Recruiting NCT01720407 Phase 3 Imiquimod cream + surgery;Placebo + surgery
6 Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna Active, not recruiting NCT01088737 Phase 2, Phase 3 Imiquimod
7 Effectiveness and Safety of Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Melasma and Facial Hyperpigmentation Not yet recruiting NCT03926845 Phase 3 Isobutylamido-thiazolyl-resorcinol Cream 0.2%;Vehicle
8 Clinical Study for the Evaluation of the Depigmenting Activity of a Cosmetic Product on Spotted Hand Skin Completed NCT02204436 Phase 3
9 Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage Completed NCT00647556 Phase 3 adapalene gel, 0.3%;tretinoin 0.05% emollient cream
10 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy Active, not recruiting NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
11 Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion Completed NCT00926952 Phase 3 Methylaminolevulinate (Metvix, Metvixia)
12 The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging Unknown status NCT02126644 Phase 2 70% glycolic acid
13 Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face Recruiting NCT02723721 Phase 2 Picato gel
14 Solar Lentigines Treatment With the Triple Combination Cream Completed NCT00975312 Phase 2 Triple combination cream;Tretinoin 0.05%
15 Side Effects of Q-Switched Ruby Laser for the Treatment of Lentigines in Light and Dark Skin Types Completed NCT00386204 Phase 2
16 Dinaciclib in Treating Patients With Stage IV Melanoma Active, not recruiting NCT00937937 Phase 2 Dinaciclib
17 Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Terminated NCT01120275 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
18 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
19 Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome Withdrawn NCT01178151 Phase 2 Everolimus
20 Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome Terminated NCT00811590 Phase 2 Everolimus
21 Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma Completed NCT00005057 Phase 1 ganciclovir
22 Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011 Unknown status NCT01249469 Not Applicable
23 Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion Unknown status NCT01136629
24 Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes Unknown status NCT02486731
25 A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy Completed NCT01778179 Not Applicable Tri-luma
26 Comparative Study of the Therapy of Solar Lentigines With a Q-switched Rubin Laser Versus a Bleaching Cream Completed NCT02153697 Not Applicable Pigmanorm Cream
27 A Single-Center 2-Arm Study for Lentigines on the Hands Completed NCT02763072 Not Applicable
28 Assessment of CRYOBEAUTY MAINS ET DECOLLETE Versus Liquid Nitrogen Cryotherapy, in the Treatment of Solar Lentigines Completed NCT03225729 Not Applicable
29 Advanced Harmonic Generation Microscopy for Treatment Assessment of Cutaneous Pigmentary Disorder Not yet recruiting NCT03578315 Not Applicable
30 Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy Completed NCT03457246 Not Applicable
31 A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin Completed NCT02385994 Not Applicable
32 Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna Completed NCT00707174 Not Applicable Imiquimod Cream;Tazarotene Cream 0.1%
33 Study for the RevLite Laser System for Facial Solar Lentigines Completed NCT02110108 Not Applicable
34 Laser Removal of Age (Sun) Spots on Hands Completed NCT01885871 Not Applicable
35 Clinical Evaluation of the Performance of a Difluoroethane-based Cyto-selective Cryotherapy to Treat Dark Spots on the Hand in 30 Volunteers. Completed NCT03157427 Not Applicable
36 Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser Completed NCT02492373 Not Applicable topical 0.05% Clobetasol propionate ointment
37 The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser Active, not recruiting NCT02427724 Not Applicable lidocaine 2.5%/prilocaine 2.5% topical anesthetic;lidocaine 7%/tetracaine 7% topical anesthetic;placebo vehicle
38 Reflectance Confocal Microscopy to Diagnose MM & LM Recruiting NCT03508297
39 Mohs and Immunofluorescence for Malignant Melanoma In Situ Withdrawn NCT02306512 Not Applicable
40 Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC) Completed NCT00668291
41 In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis Completed NCT00785369 Not Applicable
42 Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex Recruiting NCT00001452
43 Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin Not yet recruiting NCT03380845 Not Applicable
44 Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin Completed NCT00875381
45 VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation Recruiting NCT02468453 Not Applicable
46 Study of Families With Melanoma Recruiting NCT00445783
47 French Clinical Datbase of Melanoma Patients (RIC-Mel) Recruiting NCT03315468
48 Study of Accurate Diagnosis and Treatment of Peutz-Jeghers Syndrome Recruiting NCT03806075 Not Applicable
49 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
50 Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer Recruiting NCT03030404

Search NIH Clinical Center for Lentigines

Genetic Tests for Lentigines

Anatomical Context for Lentigines

MalaCards organs/tissues related to Lentigines:

42
Skin, Pituitary, Pancreas, Heart, Bone, Colon, Breast

Publications for Lentigines

Articles related to Lentigines:

(show top 50) (show all 818)
# Title Authors Year
1
Lentigines within fixed drug eruption: reply to 'Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast'. ( 30575106 )
2019
2
Importance of cardiovascular examination in patients with multiple lentigines: two cases of LEOPARD syndrome with hypertrophic cardiomyopathy. ( 29717636 )
2019
3
A prospective study evaluating the effectiveness of Q-switched ND-YAG laser (KTP) in the treatment of solar lentigines with a skin analysis device. ( 30884014 )
2019
4
UV irradiation-induced DNA hypomethylation around WNT1 gene: implications for solar lentigines. ( 31020703 )
2019
5
Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast. ( 29926507 )
2019
6
Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene. ( 30640061 )
2019
7
Innumerable lentigines in a mother and daughter. ( 30675945 )
2019
8
Efficacy and safety of intense pulsed light with a KTP filter for the treatment of solar lentigines. ( 30681160 )
2019
9
Appearance of lentigines in psoriasis patient treated with guselkumab. ( 30710906 )
2019
10
Keratinocytic Malfunction as a Trigger for the Development of Solar Lentigines. ( 30800656 )
2019
11
Nine percent of biopsy proven lentigo maligna are reclassified as lentigo maligna melanoma after surgery. ( 30716164 )
2019
12
Histologic predictors of invasion in partially biopsied lentigo maligna melanoma. ( 30879481 )
2019
13
Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. ( 31095041 )
2019
14
The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management. ( 30302753 )
2019
15
Desmoplastic Melanoma Arising after 1,064 nm q-Switched Nd:YAG Laser of a Suspected Solar Lentigo. ( 31080677 )
2019
16
Comparison of surgical margins for lentigo maligna versus melanoma in situ. ( 31014825 )
2019
17
Melanoma on Chronically Sun Damaged Skin: Lentigo Maligna and Desmoplastic Melanoma. ( 30930085 )
2019
18
Treating melanoma in situ and lentigo maligna with Mohs micrographic surgery in Australia. ( 29932208 )
2019
19
The use of 2940-nm ER:YAG laser for the treatment of lentigo maligna. ( 30933436 )
2019
20
An unusual early onset of lentigo maligna in the fourth decade of life. ( 29327697 )
2019
21
Melanocytic soluble adenylyl cyclase protein expression around lentigo maligna and in contralateral control skin. ( 30264463 )
2019
22
Follicular involvement is frequent in lentigo maligna: Implications for treatment. ( 30266559 )
2019
23
Imiquimod 5% cream in occlusion, for the treatment of lentigo maligna: A new scheme of short cycles and the need for clinical trials. ( 30285299 )
2019
24
Long-term outcomes of imiquimod-treated lentigo maligna. ( 30663131 )
2019
25
Ten Years experience using the Johnson Square Procedure for Lentigo Maligna. ( 30762226 )
2019
26
Braf-V600e immunohistochemical analyses in a series of 15, Caucasian patients affected by lentigo maligna. ( 30797564 )
2019
27
Inadequacy of Recommended Margins in the Treatment of Lentigo Maligna. ( 30888947 )
2019
28
Key dermoscopic signs in the diagnosis and progression of extrafacial lentigo maligna: Evaluation of a series of 41 cases. ( 30997681 )
2019
29
Unusual use of a common skin flap for a large cutaneous defect following Mohs surgery for lentigo maligna of the cheek: A case report. ( 31007926 )
2019
30
Efficacy of D-pigment dermocosmetic lightening product for solar lentigo lesions of the hand: A randomized controlled trial. ( 31042723 )
2019
31
Histologic Features Associated With an Invasive Component in Lentigo Maligna Lesions. ( 31066867 )
2019
32
The integration of dermoscopy and reflectance confocal microscopy improves the diagnosis of lentigo maligna. ( 31074539 )
2019
33
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. ( 29620004 )
2018
34
Pigmented actinic lichen planus (PALP) mimicking lentigo maligna melanoma: Usefulness of in vivo reflectance confocal microscopy in diagnosis and follow-up. ( 29998176 )
2018
35
Widespread keratosis pilaris in a patient with Noonan syndrome with multiple lentigines. ( 30152106 )
2018
36
Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1. ( 29114959 )
2018
37
A prospective, randomized, double-blinded, split-face pilot study comparing Q-switched 1064-nm Nd:YAG versus 532-nm Nd:YAG laser for the treatment of solar lentigines. ( 29482397 )
2018
38
Prospective study of removing solar lentigines in Asians using a novel dual-wavelength and dual-pulse width picosecond laser. ( 29608215 )
2018
39
Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab. ( 29853759 )
2018
40
Autosomal dominant progressive hyperpigmentation and lentigines in a Japanese pedigree due to a missense mutation near the C-terminus of KIT. ( 29923175 )
2018
41
Q-switched double frequency Nd:YAG 532-nm nanosecond laser vs. double frequency Nd:YAG 532-nm picosecond laser for the treatment of solar lentigines in Asians. ( 29948457 )
2018
42
Treatment of solar lentigines using a combination of picosecond laser and biophotonic treatment. ( 30214780 )
2018
43
Removal of forearm lentigines in dyschromatosis universalis hereditaria with a 755-nm Q-switched alexandrite laser. ( 29379862 )
2018
44
Noonan syndrome with multiple lentigines and associated craniosynostosis. ( 29356064 )
2018
45
Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia. ( 30548854 )
2018
46
Serial excision and Imiquimod for lentigo maligna melanoma: a proposal for a combined treatment. ( 30251811 )
2018
47
Development of Vitiligo-Like Depigmentation after Treatment of Lentigo Maligna Melanoma with 5% Imiquimod Cream. ( 30065586 )
2018
48
Staged margin-controlled excision (SMEX) for lentigo maligna melanoma in situ. ( 29936706 )
2018
49
Impact of Dermoscopy and Reflectance Confocal Microscopy on the Histopathologic Diagnosis of Lentigo Maligna/Lentigo Maligna Melanoma. ( 29933314 )
2018
50
Repair of a Complex Marginal Auricular Defect After Lentigo Maligna Melanoma Excision. ( 29933298 )
2018

Variations for Lentigines

Expression for Lentigines

Search GEO for disease gene expression data for Lentigines.

Pathways for Lentigines

Pathways related to Lentigines according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 BRAF PRKAR1A RAF1
2
Show member pathways
12.62 BRAF PRKAR1A RAF1
3
Show member pathways
12.6 BRAF PRKAR1A RAF1
4
Show member pathways
12.6 BRAF PTPN11 RAF1
5
Show member pathways
12.55 BRAF PRKAR1A RAF1
6
Show member pathways
12.51 BRAF PTPN11 RAF1
7
Show member pathways
12.46 BRAF PTPN11 RAF1
8
Show member pathways
12.44 BRAF PTPN11 RAF1
9
Show member pathways
12.39 BRAF PRKAR1A RAF1
10
Show member pathways
12.38 BRAF PRKAR1A RAF1
11
Show member pathways
12.28 PRKAR1A PTPN11 RAF1
12
Show member pathways
12.26 BRAF PTPN11 RAF1
13
Show member pathways
12.21 BRAF PTPN11 RAF1
14
Show member pathways
12.03 BRAF PRKAR1A PTPN11 RAF1
15
Show member pathways
12.02 BRAF PTPN11 RAF1
16
Show member pathways
11.98 BRAF PTPN11 RAF1
17
Show member pathways
11.96 BRAF PRKAR1A RAF1
18
Show member pathways
11.95 BRAF PRKAR1A RAF1
19
Show member pathways
11.8 BRAF PTPN11 RAF1
20 11.8 BRAF PTPN11 RAF1
21 11.76 BRAF RAF1
22 11.74 BRAF RAF1
23 11.73 BRAF RAF1
24 11.72 BRAF RAF1
25
Show member pathways
11.69 PTPN11 RAF1
26 11.68 BRAF RAF1
27 11.67 BRAF RAF1
28 11.65 BRAF PTPN11 RAF1
29
Show member pathways
11.6 BRAF RAF1
30 11.54 BRAF RAF1
31
Show member pathways
11.51 PRKAR1A PTPN11 RAF1
32 11.5 BRAF RAF1
33
Show member pathways
11.48 BRAF RAF1
34
Show member pathways
11.44 BRAF RAF1
35
Show member pathways
11.44 BRAF RAF1
36 11.44 BRAF RAF1
37 11.43 BRAF PRKAR1A RAF1
38 11.42 BRAF RAF1
39 11.37 BRAF RAF1
40 11.33 BRAF RAF1
41 11.32 BRAF RAF1
42 11.25 PTPN11 RAF1
43 11.25 PTPN11 RAF1
44 11.23 BRAF RAF1
45 11.2 MC1R PRKAR1A
46 11.09 PTPN11 RAF1
47
Show member pathways
11.04 BRAF RAF1
48 11.03 BRAF PRKAR1A RAF1
49
Show member pathways
11.02 PTPN11 RAF1
50
Show member pathways
11.01 PTPN11 RAF1

GO Terms for Lentigines

Biological processes related to Lentigines according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.67 BRAF PRKAR1A RAF1
2 platelet activation GO:0030168 9.48 PTPN11 RAF1
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.46 BRAF RAF1
4 somatic stem cell population maintenance GO:0035019 9.43 BRAF RAF1
5 heart development GO:0007507 9.43 PRKAR1A PTPN11 RAF1
6 activation of MAPKK activity GO:0000186 9.4 BRAF RAF1
7 thymus development GO:0048538 9.37 BRAF RAF1
8 thyroid gland development GO:0030878 9.32 BRAF RAF1
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.16 PTPN11 RAF1
10 face development GO:0060324 8.96 BRAF RAF1
11 intracellular signal transduction GO:0035556 8.92 BRAF MC1R PRKAR1A RAF1

Molecular functions related to Lentigines according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.43 BRAF PRKAR1A RAF1
2 MAP kinase kinase kinase activity GO:0004709 9.16 BRAF RAF1
3 small GTPase binding GO:0031267 8.96 BRAF RAF1
4 mitogen-activated protein kinase kinase binding GO:0031434 8.62 BRAF RAF1

Sources for Lentigines

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....